37.07

3.92% 1.40

Parabilis Medicines Inc (PBLS)

Overview News Price History Discussions Forecast

Parabilis Medicines Inc stock is traded at $37.07, with a volume of 290.89K. It is up +3.92% in the last 24 hours and up +19.00% over the past month. Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Previous Close:

$35.67

Open:

$35.67

24h Volume:

290.89K

Relative Volume:

0.69

Market Cap:

$4.53B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+5.97%

1M Performance:

+19.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$34.78

$37.98

1-Week Range:

$34.78

$37.98

52-Week Range:

$24.51

$37.98

Parabilis Medicines Inc Stock (PBLS) Company Profile

Name

Parabilis Medicines Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

Address

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

PBLS's Discussions on Twitter

Compare PBLS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBLS Parabilis Medicines Inc	37.07	4.58B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Parabilis Medicines Inc Stock (PBLS) Latest News

Aug 14, 2026

Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan

Aug 14, 2026

BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo

Aug 14, 2026

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha

Aug 14, 2026

Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan

Aug 13, 2026

Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine

Aug 13, 2026

Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView

Aug 13, 2026

Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com

Aug 13, 2026

Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView

Aug 13, 2026

Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com

Aug 13, 2026

Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative

Aug 13, 2026

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire

Aug 13, 2026

Aug 10, 2026

Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year HighWhat's Next? - MarketBeat

Aug 10, 2026

Aug 08, 2026

Parabilis Medicines Ord Shs (PBLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 08, 2026

Aug 07, 2026